Emerging molecular targeted therapies in the treatment of head and neck cancer
- 20 May 2009
- journal article
- review article
- Published by Informa UK Limited in Emerging Drugs
- Vol. 14 (2), 299-310
- https://doi.org/10.1517/14728210902997947
Abstract
(2009). Emerging molecular targeted therapies in the treatment of head and neck cancer. Expert Opinion on Emerging Drugs: Vol. 14, No. 2, pp. 299-310. doi: 10.1517/14728210902997947Keywords
This publication has 84 references indexed in Scilit:
- Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II studyThe Lancet Oncology, 2009
- Augmentation of Radiation Response by Panitumumab in Models of Upper Aerodigestive Tract CancerInternational Journal of Radiation Oncology*Biology*Physics, 2008
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerNew England Journal of Medicine, 2008
- Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibitionEuropean Journal Of Cancer, 2008
- Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic modelBritish Journal of Cancer, 2008
- La chimioradiothérapie des carcinomes épidermoïdes des voies aérodigestives supérieures : point sur les thérapeutiques cibléesCancer/Radiothérapie, 2008
- Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): An UpdateInternational Journal of Radiation Oncology*Biology*Physics, 2007
- Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenograftsBritish Journal of Cancer, 2007
- EGFR targeting therapies: Monoclonal antibodies versus tyrosine kinase inhibitors: Similarities and differencesCritical Reviews in Oncology/Hematology, 2007
- Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126British Journal of Cancer, 2006